
-
Vor Biopharma NASDAQ:VOR Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.
Location: | Website: www.vorbiopharma.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
29.78M
Cash
91.93M
Avg Qtr Burn
-24.92M
Short % of Float
3.37%
Insider Ownership
31.93%
Institutional Own.
49.49%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Trem-cel (VOR33) + Mylotarg (VBP101) Details Acute myeloid leukemia, Myelodysplastic syndrome | Phase 1/2 Data readout | |
Phase 1/2 Data readout | ||
Trem-cel (VOR33) + VCAR33 Details Acute myeloid leukemia | Phase 1 Initiation |